Information about GlobalPharmacyMeds.to
List of countries where we can ship Carfilzomib:
Latest news releases on Carfilzomib:
Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor.
KYPROLIS® (carfilzomib) is a treatment option for people who have already received 1 or more previous treatments for relapsed multiple myeloma. Learn more here.
Anwendungsgebiet gemäß Fachinformation für Carfilzomib (Kyprolis®) „Kyprolis ist in Kombination mit entweder Lenalidomid und Dexamethason oder Dexamethason ...
Carfilzomib • control hypertension prior to starting carfilzomib and monitor throughout treatment; hypertensive crisis and emergency have occurred2
FDA approval history for Kyprolis (carfilzomib) used to treat Multiple Myeloma. Supplied by Amgen Inc.
• Carfilzomib (kar filz' oh mib) is a drug that is used to treat some types of cancer. It is a clear liquid that is injected into a vein. • Tell your doctor if ...
The purpose of the study is to assess the safety, tolerability and activity of a once-weekly regimen of carfilzomib in combination with lenalidomide and dexamethasone ...
The supportive therapies (e.g. antiemetics, premedications, etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults.
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients (Myeloma XI)
Learn about the mechanism of action of KYRPOLIS (carfilzomib), a second-generation proteasome inhibitor, for patients with relapsed or refactory multiple myeloma.